You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

REQUIP Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Requip, and what generic alternatives are available?

Requip is a drug marketed by Glaxosmithkline Llc and is included in two NDAs.

The generic ingredient in REQUIP is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.

Summary for REQUIP
Drug patent expirations by year for REQUIP
Drug Prices for REQUIP

See drug prices for REQUIP

Drug Sales Revenue Trends for REQUIP

See drug sales revenues for REQUIP

Recent Clinical Trials for REQUIP

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Titan PharmaceuticalsPhase 1/Phase 2
Vanderbilt University Medical CenterPhase 4
Seoul National University HospitalPhase 4

See all REQUIP clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for REQUIP
Paragraph IV (Patent) Challenges for REQUIP
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
REQUIP Tablets ropinirole hydrochloride 3 mg, 4 mg and 5 mg 020658 1 2005-02-04
REQUIP Tablets ropinirole hydrochloride 0.25 mg, 0.5 mg, 1 mg and 2 mg 020658 1 2004-12-22

US Patents and Regulatory Information for REQUIP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-001 Sep 19, 1997 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-005 Sep 19, 1997 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-004 Sep 19, 1997 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-004 Jun 13, 2008 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REQUIP

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-004 Sep 19, 1997 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-001 Sep 19, 1997 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-003 Sep 19, 1997 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-005 Sep 19, 1997 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-003 Sep 19, 1997 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for REQUIP

See the table below for patents covering REQUIP around the world.

Country Patent Number Title Estimated Expiration
Greece 3007251 ⤷  Try a Trial
Israel 70311 4-AMINOALKYL-2(3H)-INDOLONES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ⤷  Try a Trial
Austria 83659 ⤷  Try a Trial
Denmark 156514 ⤷  Try a Trial
Finland 77849 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for REQUIP

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0113964 97C0037 Belgium ⤷  Try a Trial PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
0113964 SPC/GB96/039 United Kingdom ⤷  Try a Trial SPC/GB96/039: 20031130, EXPIRES: 20081129
0299602 C970006 Netherlands ⤷  Try a Trial PRODUCT NAME: ROPINIROLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAA RDBAAR ZOUT, IN HET BIJZONDER HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 20761 - RVG 20765 19961202; FIRST REGISTRATION: GB PL 10592/0085 19960702
0299602 97C0036 Belgium ⤷  Try a Trial PRODUCT NAME: CHLORHYDRATE DE ROPINIROLE (=ROPINIROLE); NAT. REGISTRATION NO/DATE: 981 IS 120 F 3 19970414; FIRST REGISTRATION: GB PL 10592/0085 19960702
0299602 SPC/GB96/040 United Kingdom ⤷  Try a Trial PRODUCT NAME: ROPINIROLE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: UK 10592/0085 19960702
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.